Narrowing the Equity Gap: The Impact of California’s 2022 Medicaid Expansion on Access to SGLT-2 Inhibitors and GLP-1 RAs in Older Undocumented Immigrants

Narrowing the Equity Gap: The Impact of California’s 2022 Medicaid Expansion on Access to SGLT-2 Inhibitors and GLP-1 RAs in Older Undocumented Immigrants

This review analyzes the significant shift in type 2 diabetes prescribing patterns following California's 2022 Medi-Cal expansion, highlighting how policy-driven access to SGLT-2 inhibitors and GLP-1 receptor agonists narrowed health equity gaps for older undocumented populations.
The Long Shadow of the ICU: Identifying High-Risk Functional Trajectories in Older Survivors

The Long Shadow of the ICU: Identifying High-Risk Functional Trajectories in Older Survivors

A large-scale longitudinal study reveals that ICU survivors aged 60–79 face significantly higher 5-year excess mortality and functional decline compared to the general population, whereas outcomes for nonagenarians converge with their peers, highlighting a critical window for geriatric intervention and advance care planning.
High-Dose Influenza Vaccination Reduces Hospitalizations and Cardiovascular Events in Older Adults: Insights from the FLUNITY-HD Pooled Analysis

High-Dose Influenza Vaccination Reduces Hospitalizations and Cardiovascular Events in Older Adults: Insights from the FLUNITY-HD Pooled Analysis

The FLUNITY-HD pooled analysis of over 466,000 older adults demonstrates that high-dose inactivated influenza vaccine (HD-IIV) significantly reduces hospitalizations for influenza, pneumonia, and cardiovascular causes, including a 21.3% reduction in heart failure admissions, compared to standard-dose vaccines.
Individualized Feedback Letters Fail to Reduce Long-Term Alcohol Consumption: Insights from a 4-Year RCT

Individualized Feedback Letters Fail to Reduce Long-Term Alcohol Consumption: Insights from a 4-Year RCT

A 4-year randomized controlled trial found that computer-generated feedback letters failed to reduce alcohol consumption in the general population. Unexpectedly, the control group showed greater reduction at 48 months, suggesting that current digital intervention strategies may require significant adaptation for low-risk drinkers.
Optimizing Opioid Use Disorder Treatment: When Does 300 mg Outperform 100 mg of Extended-Release Buprenorphine?

Optimizing Opioid Use Disorder Treatment: When Does 300 mg Outperform 100 mg of Extended-Release Buprenorphine?

This randomized clinical trial compares 100-mg and 300-mg maintenance doses of extended-release buprenorphine. While overall efficacy was similar, the 300-mg dose significantly improved abstinence among patients with high-frequency fentanyl use, suggesting a need for dose-intensification in the era of potent synthetic opioids.